NovaBay Pharmaceuticals, Inc. (NBY): Price and Financial Metrics


NovaBay Pharmaceuticals, Inc. (NBY): $2.47

-0.01 (-0.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NBY to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NBY POWR Grades

  • Value is the dimension where NBY ranks best; there it ranks ahead of 86.46% of US stocks.
  • NBY's strongest trending metric is Value; it's been moving up over the last 33 days.
  • NBY ranks lowest in Momentum; there it ranks in the 4th percentile.

NBY Stock Summary

  • NBY has a market capitalization of $4,599,318 -- more than approximately only 0.77% of US stocks.
  • With a year-over-year growth in debt of 1,001.02%, NOVABAY PHARMACEUTICALS INC's debt growth rate surpasses 97.91% of about US stocks.
  • In terms of volatility of its share price, NBY is more volatile than 99.07% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to NOVABAY PHARMACEUTICALS INC, a group of peers worth examining would be GROW, EBF, IZEA, ZUMZ, and DTEA.
  • Visit NBY's SEC page to see the company's official filings. To visit the company's web site, go to www.novabay.com.

NBY Valuation Summary

  • In comparison to the median Healthcare stock, NBY's price/sales ratio is 80.95% lower, now standing at 0.4.
  • NBY's price/sales ratio has moved down 16.7 over the prior 186 months.

Below are key valuation metrics over time for NBY.

Stock Date P/S P/B P/E EV/EBIT
NBY 2023-01-30 0.4 0.3 -0.5 -1.1
NBY 2023-01-27 0.4 0.3 -0.5 -1.0
NBY 2023-01-26 0.3 0.3 -0.4 -0.8
NBY 2023-01-25 0.3 0.3 -0.4 -0.8
NBY 2023-01-24 0.3 0.3 -0.5 -0.9
NBY 2023-01-23 0.3 0.3 -0.5 -0.9

NBY Growth Metrics

    The 2 year cash and equivalents growth rate now stands at -1.17%.
  • Its 5 year net income to common stockholders growth rate is now at 34.8%.
  • Its 5 year cash and equivalents growth rate is now at -22.85%.
NBY's revenue has moved up $5,542,000 over the prior 33 months.

The table below shows NBY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 12.141 -9.763 -8.952
2022-06-30 10.155 -9.542 -5.448
2022-03-31 9.243 -9.83 -5.152
2021-12-31 8.421 -9.192 -6.559
2021-09-30 7.668 -6.319 -7.42
2021-06-30 7.998 -6.221 -8.352

NBY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NBY has a Quality Grade of C, ranking ahead of 44.35% of graded US stocks.
  • NBY's asset turnover comes in at 0.533 -- ranking 79th of 680 Pharmaceutical Products stocks.
  • AMGN, AMRN, and UTHR are the stocks whose asset turnover ratios are most correlated with NBY.

The table below shows NBY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.533 0.698 -7.529
2021-03-31 0.660 0.610 -9.044
2020-12-31 0.722 0.600 -7.838
2020-09-30 0.764 0.615 -6.542
2020-06-30 0.757 0.607 -3.607
2020-03-31 0.620 0.717 -1.768

NBY Stock Price Chart Interactive Chart >

Price chart for NBY

NBY Price/Volume Stats

Current price $2.47 52-week high $12.96
Prev. close $2.48 52-week low $1.24
Day low $2.34 Volume 39,400
Day high $2.58 Avg. volume 73,605
50-day MA $1.98 Dividend yield N/A
200-day MA $5.60 Market Cap 4.63M

NovaBay Pharmaceuticals, Inc. (NBY) Company Bio


NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products for the eye care market in the United States. The company was founded in 2000 and is based in Emeryville, California.


NBY Latest News Stream


Event/Time News Detail
Loading, please wait...

NBY Latest Social Stream


Loading social stream, please wait...

View Full NBY Social Stream

Latest NBY News From Around the Web

Below are the latest news stories about NOVABAY PHARMACEUTICALS INC that investors may wish to consider to help them evaluate NBY as an investment opportunity.

PhaseOne Health and NovaBay Pharmaceuticals to Expand Commercial and Collaborative Strategies for the Wound Care Market

NASHVILLE, Tenn. & EMERYVILLE, Calif., January 17, 2023--PhaseOne Health announces the expansion of its commercial program for PhaseOne Skin and Wound Care Cleanser through collaborative partnerships with innovative wound dressing manufacturers and key wound and burn care specialists in the United States. PhaseOne is formulated with NovaBay Pharmaceuticals’ (NYSE American: NBY) patented, stable hypochlorous acid.

Yahoo | January 17, 2023

Can you now get a good deal on NovaBay Pharmaceuticals Inc.’s shares?

In Friday’s session, NovaBay Pharmaceuticals Inc. (AMEX:NBY) marked $1.95 per share, up from $1.39 in the previous session. While NovaBay Pharmaceuticals Inc. has overperformed by 40.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NBY fell by -85.71%, with highs and lows ranging from $14.97 to […]

US Post News | January 3, 2023

NBY, RSLS and FORA among healthcare movers

Gainers: Palisade Bio PALI +65%.Silo Pharma (SILO) +57%.F-star Therapeutics FSTX +42%.NovaBay Pharmaceuticals (NBY) +31%.Kala Pharmaceuticals KALA +29%.Losers: Hoth…

Seeking Alpha | December 30, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday!

William White on InvestorPlace | December 14, 2022

NovaBay Pharmaceuticals Announces the Launch of DERMAdoctor’s TikTok Store in China and Expands Online Marketing in the U.S. and China

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the expansion of its lifestyle promotional video campaigns on TikTok and its Chinese cou

Business Wire | November 29, 2022

Read More 'NBY' Stories Here

NBY Price Returns

1-mo 5.11%
3-mo -30.13%
6-mo -74.88%
1-year -77.96%
3-year -87.87%
5-year -98.05%
YTD 26.67%
2022 -85.21%
2021 -45.97%
2020 8.91%
2019 -16.88%
2018 -80.00%

Continue Researching NBY

Want to see what other sources are saying about NovaBay Pharmaceuticals Inc's financials and stock price? Try the links below:

NovaBay Pharmaceuticals Inc (NBY) Stock Price | Nasdaq
NovaBay Pharmaceuticals Inc (NBY) Stock Quote, History and News - Yahoo Finance
NovaBay Pharmaceuticals Inc (NBY) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7996 seconds.